Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...

About Dupixent Dupixent is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available for COPD. Dupixent is intended for injection under the skin (subcutaneous ...

Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...

CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update.

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...

Recent studies examine the burden of CRSwNP, looking at quality of life in patients and caregivers and assessing how CRSwNP ...

In fact, if you have either asthma or allergic rhinitis, you may be at a higher risk of developing chronic sinusitis. Both conditions cause inflammation that can impact the airways and sinuses.

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...